Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?

Journal of Controlled Release

Volumn 164, Issue 3, 2012, Pages 265-275

  Taurin, Sebastien ^a   Nehoff, Hayley ^a   Greish, Khaled ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Drug targeting; Enhanced permeability and retention (EPR); Nanomedicine; Pharmacokinetics; Tumor vessel; Vascular permeability

Indexed keywords

ANIMAL MODEL; ANTI-CANCER AGENTS; CLINICAL USE; DELIVERY SYSTEMS; DRUG-TARGETING; ENHANCED PERMEABILITY AND RETENTION EFFECTS; ENHANCED PERMEABILITY AND RETENTIONS; PHYSICOCHEMICAL CHARACTERISTICS; POLYMER CONJUGATE; TUMOR BIOLOGY; TUMOR MODELS; TUMOR TARGETING; TUMOR TISSUES; TUMOR VESSELS; VASCULAR PERMEABILITY;

LIPOSOMES; MEDICAL NANOTECHNOLOGY; PHARMACOKINETICS;

TUMORS;

ASPARAGINASE MACROGOL; CAMPTOTHECIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GOLD NANOPARTICLE; MACROGOL; MIFAMURTIDE; PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; BIOCOMPATIBILITY; BRAIN CANCER; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CIRCULATION; COLORECTAL CANCER; CONFERENCE PAPER; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; ENDOCYTOSIS; ENDOMETRIUM CANCER; ENHANCED PERMEABILITY AND RETENTION; HEAD AND NECK CANCER; HUMAN; IMMUNE SYSTEM; IN VIVO STUDY; INFLAMMATION; INTERNALIZATION; KAPOSI SARCOMA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT LYMPHOMATOUS MENINGITIS; MALIGNANT NEOPLASTIC DISEASE; NANOMEDICINE; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PARTICLE SIZE; PHAGOCYTOSIS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROSTATE CANCER; RETICULOENDOTHELIAL SYSTEM; SKIN CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; CAPILLARY PERMEABILITY; DRUG CARRIERS; DRUG DESIGN; HUMANS; LYSOSOMES; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS; SOLUBILITY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84870236985     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.013     Document Type: Conference Paper

References (195)

1. E. Goldmann The growth of malignant disease in man and the lower animals, with special reference to the vascular system Proc. R. Soc. Med. 1 1908 1 13
2. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 years of progress Nat. Rev. Cancer 8 2008 473 480
3. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
4. J.C. Underwood, and I. Carr The ultrastructure and permeability characteristics of the blood vessels of a transplantable rat sarcoma J. Pathol. 107 1972 157 166
5. H.I. Peterson, and K.L. Appelgren Experimental studies on the uptake and rentention of labelled proteins in a rat tumour Eur. J. Cancer 9 1973 543 547
6. J.D. Ward, M.G. Hadfield, D.P. Becker, and E.T. Lovings Endothelial fenestrations and other vascular alterations in primary melanoma of the central nervous system Cancer 34 1974 1982 1991
7. N.B. Ackerman, and P.A. Hechmer Studies on the capillary permeability of experimental liver metastases Surg. Gynecol. Obstet. 146 1978 884 888
8. H. Maeda, K. Greish, and J. Fang The EPR Effect And Polymeric Drugs: A Paradigm Shift for Cancer Chemotherapy in the 21st Century 2006 Springer Heidelberg, Germany
9. D.R. Senger, C.A. Perruzzi, J. Feder, and H.F. Dvorak A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines Cancer Res. 46 1986 5629 5632
10. S.M. Weis, and D.A. Cheresh Pathophysiological consequences of VEGF-induced vascular permeability Nature 437 2005 497 504
11. N. Ferrara, and B. Keyt Vascular endothelial growth factor: basic biology and clinical implications EXS 79 1997 209 232
12. J.A. Nagy, S.H. Chang, A.M. Dvorak, and H.F. Dvorak Why are tumour blood vessels abnormal and why is it important to know? Br. J. Cancer 100 2009 865 869
13. J.A. Nagy, A.M. Dvorak, and H.F. Dvorak Vascular hyperpermeability, angiogenesis, and stroma generation Cold Spring Harb. Perspect. Med. 2 2012 a006544
14. H. Maeda, and Y. Matsumura Tumoritropic and lymphotropic principles of macromolecular drugs Crit. Rev. Ther. Drug Carrier Syst. 6 1989 193 210
15. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 46 1986 6387 6392
16. H. Maeda, J. Fang, T. Inutsuka, and Y. Kitamoto Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int. Immunopharmacol. 3 2003 319 328
17. H. Maeda, J. Takeshita, and R. Kanamaru A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic Int. J. Pept. Protein Res. 14 1979 81 87
18. H.S. Choi, W. Liu, P. Misra, E. Tanaka, J.P. Zimmer, B. Itty Ipe, M.G. Bawendi, and J.V. Frangioni Renal clearance of quantum dots Nat. Biotechnol. 25 2007 1165 1170
19. H. Sarin Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability J. Angiogenes. Res. 2 2010 14
20. K. Greish Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines J. Drug Target. 15 2007 457 464
21. K. Greish Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting Methods Mol. Biol. 624 2010 25 37
22. M.M. Arnida, A. Janát-Amsbury, C.M. Ray, and H. Peterson Ghandehari, Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages Eur. J. Pharm. Biopharm. 77 2011 417 423
23. S.M. Moghimi, A.C. Hunter, and J.C. Murray Long-circulating and target-specific nanoparticles: theory to practice Pharmacol. Rev. 53 2001 283 318
24. Y. Zhu, L. Che, H. He, Y. Jia, J. Zhang, and X. Li Highly efficient nanomedicines assembled via polymer-drug multiple interactions: tissue-selective delivery carriers J. Control. Release 152 2011 317 324
25. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1 2006 297 315
26. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
27. N.D. James, R.J. Coker, D. Tomlinson, J.R. Harris, M. Gompels, A.J. Pinching, and J.S. Stewart Liposomal doxorubicin (Doxil): an effective new treatment for Kaposi's sarcoma in AIDS Clin. Oncol. 6 1994 294 296
28. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration J. Int. Assoc. Physicians AIDS Care 2 5 May 1996 50 51
29. B.S. Chhikara, and K. Parang Development of cytarabine prodrugs and delivery systems for leukemia treatment Expert Opin. Drug Deliv. 7 2010 1399 1414
30. C.E. Swenson, L.E. Bolcsak, G. Batist, T.H. Guthrie Jr., K.H. Tkaczuk, H. Boxenbaum, L. Welles, S.C. Chow, R. Bhamra, and P. Chaikin Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer Anticancer Drugs 14 2003 239 246
31. K. Ando, K. Mori, N. Corradini, F. Redini, and D. Heymann Mifamurtide for the treatment of nonmetastatic osteosarcoma Expert. Opin. Pharmacother. 12 2011 285 292
32. P.A. Dinndorf, J. Gootenberg, M.H. Cohen, P. Keegan, and R. Pazdur FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL) Oncologist 12 2007 991 998
33. C. Oerlemans, W. Bult, M. Bos, G. Storm, J.F. Nijsen, and W.E. Hennink Polymeric micelles in anticancer therapy: targeting, imaging and triggered release Pharm. Res. 27 2010 2569 2589
34. H. Maeda, G.Y. Bharate, and J. Daruwalla Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect Eur. J. Pharm. Biopharm. 71 2009 409 419
35. W.J. Gradishar Albumin-bound paclitaxel: a next-generation taxane Expert. Opin. Pharmacother. 7 2006 1041 1053
36. G. Morana, E. Salviato, and A. Guarise Contrast agents for hepatic MRI Cancer Imaging 7 2007 S24 S27 (Spec No A)
37. C.W. Jung Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil Magn. Reson. Imaging 13 1995 675 691
38. Y. Noguchi, J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike, and H. Maeda Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues Jpn. J. Cancer Res. 89 1998 307 314
39. L.W. Seymour, Y. Miyamoto, H. Maeda, M. Brereton, J. Strohalm, K. Ulbrich, and R. Duncan Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier Eur. J. Cancer 31A 1995 766 770
40. M. Sharpe, S.E. Easthope, G.M. Keating, and H.M. Lamb Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma Drugs 62 2002 2089 2126
41. P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari Intravascular delivery of particulate systems: does geometry really matter? Pharm. Res. 26 2009 235 243
42. M.E. Davis, Z.G. Chen, and D.M. Shin Nanoparticle therapeutics: an emerging treatment modality for cancer Nat. Rev. Drug Discov. 7 2008 771 782
43. V.P. Torchilin Micellar nanocarriers: pharmaceutical perspectives Pharm. Res. 24 2007 1 16
44. I. Brigger, C. Dubernet, and P. Couvreur Nanoparticles in cancer therapy and diagnosis Adv. Drug Deliv. Rev. 54 2002 631 651
45. S.P. Herbert, and D.Y. Stainier Molecular control of endothelial cell behaviour during blood vessel morphogenesis Nat. Rev. Mol. Cell Biol. 12 2011 551 564
46. E.E. Graves, A. Maity, and Q.T. Le The tumor microenvironment in non-small-cell lung cancer Semin. Radiat. Oncol. 20 2010 156 163
47. J. Fang, H. Nakamura, and H. Maeda The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect Adv. Drug Deliv. Rev. 63 2011 136 151
48. J. Wu, T. Akaike, and H. Maeda Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger Cancer Res. 58 1998 159 165
49. A.K. Iyer, G. Khaled, J. Fang, and H. Maeda Exploiting the enhanced permeability and retention effect for tumor targeting Drug Discov. Today 11 2006 812 818
50. H. Maeda Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting, Proceedings of the Japan Academy Series B, Physical and Biological Sciences 88 2012 53 71
51. S. Van, S.K. Das, X. Wang, Z. Feng, Y. Jin, Z. Hou, F. Chen, A. Pham, N. Jiang, S.B. Howell, and L. Yu Synthesis, characterization, and biological evaluation of poly(L-gamma-glutamyl-glutamine)- paclitaxel nanoconjugate Int. J. Nanomedicine 5 2010 825 837
52. R. Duncan, M.J. Vicent, F. Greco, and R.I. Nicholson Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer Endocr. Relat. Cancer 12 2005 S189 S199
53. J.M. Meerum Terwogt, W.W. ten Bokkel Huinink, J.H. Schellens, M. Schot, I.A. Mandjes, M.G. Zurlo, M. Rocchetti, H. Rosing, F.J. Koopman, and J.H. Beijnen Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel Anticancer Drugs 12 2001 315 323
54. F.M. Wachters, H.J. Groen, J.G. Maring, J.A. Gietema, M. Porro, H. Dumez, E.G. de Vries, and A.T. van Oosterom A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours Br. J. Cancer 90 2004 2261 2267
55. N.E. Schoemaker, C. van Kesteren, H. Rosing, S. Jansen, M. Swart, J. Lieverst, D. Fraier, M. Breda, C. Pellizzoni, R. Spinelli, M. Grazia Porro, J.H. Beijnen, J.H. Schellens, and W.W. ten Bokkel Huinink A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin Br. J. Cancer 87 2002 608 614
56. N.M. Zaki, and N. Tirelli Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting Expert Opin. Drug Deliv. 7 2010 895 913
57. M.L. Macheda, S. Rogers, and J.D. Best Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer J. Cell. Physiol. 202 2005 654 662
58. Z. Hu, F. Luo, Y. Pan, C. Hou, L. Ren, J. Chen, J. Wang, and Y. Zhang Arg-Gly-Asp (RGD) peptide conjugated poly(lactic acid)-poly(ethylene oxide) micelle for targeted drug delivery J. Biomed. Mater. Res. A 85 2008 797 807
59. Y. Zhang, M. Yang, N.G. Portney, D. Cui, G. Budak, E. Ozbay, M. Ozkan, and C.S. Ozkan Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells Biomed. Microdevices 10 2008 321 328
60. T. Yu, A. Malugin, and H. Ghandehari Impact of silica nanoparticle design on cellular toxicity and hemolytic activity ACS Nano 5 2011 5717 5728
61. D. Landesman-Milo, and D. Peer Altering the immune response with lipid-based nanoparticles J. Control. Release 161 2012 600 608
62. M.A. Dobrovolskaia, and S.E. McNeil Immunological properties of engineered nanomaterials Nat. Nanotechnol. 2 2007 469 478
63. A.L. Klibanov, K. Maruyama, V.P. Torchilin, and L. Huang Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes FEBS Lett. 268 1990 235 237
64. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U. S. A. 88 1991 11460 11464
65. J. Senior, C. Delgado, D. Fisher, C. Tilcock, and G. Gregoriadis Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles Biochim. Biophys. Acta 1062 1991 77 82
66. J.H. Senior Fate and behavior of liposomes in vivo: a review of controlling factors Crit. Rev. Ther. Drug Carrier Syst. 3 1987 123 193
67. V.P. Torchilin, V.G. Omelyanenko, M.I. Papisov, A.A. Bogdanov Jr., V.S. Trubetskoy, J.N. Herron, and C.A. Gentry Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity Biochim. Biophys. Acta 1195 1994 11 20
68. J.G. Shiah, M. Dvořák, P. Kopečková, Y. Sun, C.M. Peterson, and J. Kopeček Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice Eur. J. Cancer 37 2001 131 139
69. D.D. Lasic, F.J. Martin, A. Gabizon, S.K. Huang, and D. Papahadjopoulos Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times Biochim. Biophys. Acta 1070 1991 187 192
70. V. Dixit, J. Van den Bossche, D.M. Sherman, D.H. Thompson, and R.P. Andres Synthesis and grafting of thioctic acid-PEG-folate conjugates onto Au nanoparticles for selective targeting of folate receptor-positive tumor cells Bioconjug. Chem. 17 2006 603 609
71. N.C. Bellocq, S.H. Pun, G.S. Jensen, and M.E. Davis Transferrin- containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery Bioconjug. Chem. 14 2003 1122 1132
72. M. Breunig, S. Bauer, and A. Goepferich Polymers and nanoparticles: intelligent tools for intracellular targeting? Eur. J. Pharm. Biopharm. 68 2008 112 128
73. B. Haley, and E. Frenkel Nanoparticles for drug delivery in cancer treatment Urol. Oncol. Semin. Orig. Investig. 26 2008 57 64
74. K.N. Sugahara, T. Teesalu, P.P. Karmali, V.R. Kotamraju, L. Agemy, D.R. Greenwald, and E. Ruoslahti Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs Science 328 2010 1031 1035
75. R.K. Jain, and T. Stylianopoulos Delivering nanomedicine to solid tumors Nat. Rev. Clin. Oncol. 7 2010 653 664
76. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, D. Fukumura, and R.K. Jain Normalization of the vasculature for treatment of cancer and other diseases Physiol. Rev. 91 2011 1071 1121
77. M.D. Howard, A. Ponta, A. Eckman, M. Jay, and Y. Bae Polymer micelles with hydrazone-ester dual linkers for tunable release of dexamethasone Pharm. Res. 28 2011 2435 2446
78. K. Greish, J. Fang, T. Inutsuka, A. Nagamitsu, and H. Maeda Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting Clin. Pharmacokinet. 42 2003 1089 1105
79. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 2003 347 360
80. B. Mezquita, J. Mezquita, M. Pau, and C. Mezquita A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells J. Cell. Biochem. 110 2010 732 742
81. T.H. Lee, S. Seng, M. Sekine, C. Hinton, Y. Fu, H.K. Avraham, and S. Avraham Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1 PLoS Med. 4 2007 e186
82. A.V. Timoshenko, S. Rastogi, and P.K. Lala Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells Br. J. Cancer 97 2007 1090 1098
83. A.V. Timoshenko, C. Chakraborty, G.F. Wagner, and P.K. Lala COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer Br. J. Cancer 94 2006 1154 1163
84. P. Laakkonen, M. Waltari, T. Holopainen, T. Takahashi, B. Pytowski, P. Steiner, D. Hicklin, K. Persaud, J.R. Tonra, L. Witte, and K. Alitalo Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth Cancer Res. 67 2007 593 599
85. T.E. Fitzpatrick, G.E. Lash, A. Yanaihara, D.S. Charnock-Jones, S.K. Macdonald-Goodfellow, and C.H. Graham Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor Exp. Cell Res. 283 2003 247 255
86. M. Weigand, P. Hantel, R. Kreienberg, and J. Waltenberger Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro Angiogenesis 8 2005 197 204
87. A. Hoeben, B. Landuyt, M.S. Highley, H. Wildiers, A.T. Van Oosterom, and E.A. De Bruijn Vascular endothelial growth factor and angiogenesis Pharmacol. Rev. 56 2004 549 580
88. L. Ryden, M. Stendahl, H. Jonsson, S. Emdin, N.O. Bengtsson, and G. Landberg Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response Breast Cancer Res. Treat. 89 2005 135 143
89. M. Schmidt, H.U. Voelker, M. Kapp, J. Dietl, and U. Kammerer Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage Anticancer. Res. 28 2008 1719 1724
90. N. Ravindranath, D. Wion, P. Brachet, and D. Djakiew Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate J. Androl. 22 2001 432 443
91. Y. Zeng, K. Opeskin, J. Goad, and E.D. Williams Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis Cancer Res. 66 2006 9566 9575
92. M. Li, H. Chen, L. Diao, Y. Zhang, C. Xia, and F. Yang Caveolin-1 and VEGF-C promote lymph node metastasis in the absence of intratumoral lymphangiogenesis in non-small cell lung cancer Tumori 96 2010 734 743
93. R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, A. Albini, A. Ryan, F. Ciardiello, and G. Tortora Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells Clin. Cancer Res. 14 2008 5069 5080
94. Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics Cancer Res. 64 2004 3365 3370
95. J. Yang, H.F. Wu, L.X. Qian, W. Zhang, L.X. Hua, M.L. Yu, Z. Wang, Z.Q. Xu, Y.G. Sui, and X.R. Wang Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression Asian J. Androl. 8 2006 169 175
96. N.R. Smith, D. Baker, N.H. James, K. Ratcliffe, M. Jenkins, S.E. Ashton, G. Sproat, R. Swann, N. Gray, A. Ryan, J.M. Jurgensmeier, and C. Womack Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers Clin. Cancer Res. 16 2010 3548 3561
97. N. Simiantonaki, C. Jayasinghe, R. Michel-Schmidt, K. Peters, M.I. Hermanns, and C.J. Kirkpatrick Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines Int. J. Oncol. 32 2008 585 592
98. M.P. Morelli, A.M. Brown, T.M. Pitts, J.J. Tentler, F. Ciardiello, A. Ryan, J.M. Jurgensmeier, and S.G. Eckhardt Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines Mol. Cancer Ther. 8 2009 2546 2558
99. T. Niki, S. Iba, M. Tokunou, T. Yamada, Y. Matsuno, and S. Hirohashi Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma Clin. Cancer Res. 6 2000 2431 2439
100. E. Martinelli, T. Troiani, F. Morgillo, G. Rodolico, D. Vitagliano, M.P. Morelli, C. Tuccillo, L. Vecchione, A. Capasso, M. Orditura, F. De Vita, S.G. Eckhardt, M. Santoro, L. Berrino, and F. Ciardiello Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells Clin. Cancer Res. 16 2010 4990 5001
101. V.K. Anagnostou, D.G. Tiniakos, M. Fotinou, A. Achimastos, and K.N. Syrigos Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients Virchows Arch. 458 2011 331 340
102. E. Carrillo de Santa Pau, F.C. Arias, E. Caso Pelaez, G.M. Munoz Molina, I. Sanchez Hernandez, I. Muguruza Trueba, R. Moreno Balsalobre, S. Sacristan Lopez, A. Gomez Pinillos, and M. del Val Toledo Lobo Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer Cancer 115 2009 1701 1712
103. E. Zygalaki, E.G. Tsaroucha, L. Kaklamanis, and E.S. Lianidou Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer Clin. Chem. 53 2007 1433 1439
104. Y.H. Bae, and K. Park Targeted drug delivery to tumors: myths, reality and possibility J. Control. Release 153 2011 198 205
105. R. Kedmi, N. Ben-Arie, and D. Peer The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation Biomaterials 31 2010 6867 6875
106. J.M. Anderson, A. Rodriguez, and D.T. Chang Foreign body reaction to biomaterials Semin. Immunol. 20 2008 86 100
107. S. Mukhopadhyay, and A.A. Gal Granulomatous lung disease: an approach to the differential diagnosis Arch. Pathol. Lab. Med. 134 2010 667 690
108. L.A.J. O'Neill How frustration leads to inflammation Science 320 2008 619 620
109. J. Panyam, and V. Labhasetwar Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles Mol. Pharm. 1 2004 77 84
110. T. Etrych, L. Kovář, J. Strohalm, P. Chytil, B. Říhová, and K. Ulbrich Biodegradable star HPMA polymer-drug conjugates: Biodegradability, distribution and anti-tumor efficacy J. Control. Release 154 2011 241 248
111. M. Dvořák, P. Kopečková, and J. Kopeček High-molecular weight HPMA copolymer-adriamycin conjugates J. Control. Release 60 1999 321 332
112. J.L. Yu, and J.W. Rak Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis Breast Cancer Res. 5 2003 83 88
113. J.W. Pollard Macrophages define the invasive microenvironment in breast cancer J. Leukoc. Biol. 84 2008 623 630
114. T.M. Robinson-Smith, I. Isaacsohn, C.A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M.M. McFarland-Mancini, and A.F. Drew Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice Cancer Res. 67 2007 5708 5716
115. L.W. Seymour, D.R. Ferry, D. Anderson, S. Hesslewood, P.J. Julyan, R. Poyner, J. Doran, A.M. Young, S. Burtles, D.J. Kerr, and f.t.C.R.C.P.I.I.C.T. Committee Hepatic drug targeting: Phase I evaluation of polymer-bound doxorubicin J. Clin. Oncol. 20 2002 1668 1676
116. Z.M. Qian, H. Li, H. Sun, and K. Ho Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway Pharmacol. Rev. 54 2002 561 587
117. S. Wang, and P.S. Low Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells J. Control. Release 53 1998 39 48
118. T. Lammers, F. Kiessling, W.E. Hennink, and G. Storm Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress J. Control. Release 161 2012 175 187
119. A. Garcia-Bennett, M. Nees, and B. Fadeel In search of the Holy Grail: folate-targeted nanoparticles for cancer therapy Biochem. Pharmacol. 81 2011 976 984
120. H.T. Winer-Muram, S.G. Jennings, R.D. Tarver, A.M. Aisen, M. Tann, D.J. Conces, and C.A. Meyer Volumetric growth rate of stage I lung cancer prior to treatment: serial CT scanning Radiology 223 2002 798 805
121. K. Wechsler-Jentzsch, J.H. Witt, C.R. Fitz, D.C. McCullough, and L. Harisiadis Unresectable gliomas in children: tumor-volume response to radiation therapy Radiology 169 1988 237 242
122. T. Kuroishi, S. Tominaga, T. Morimoto, H. Tashiro, S. Itoh, H. Watanabe, M. Fukuda, J. Ota, T. Horino, and T. Ishida Tumor growth rate and prognosis of breast cancer mainly detected by mass screening Jpn. J. Cancer Res. 81 1990 454 462
123. G.M. Zharinov, and V.A. Gushchin The rate of tumor growth and cell loss in cervical cancer Vopr. Onkol. 35 1989 21 25
124. E. Strom, and J.L. Larsen Colon cancer at barium enema examination and colonoscopy: a study from the county of Hordaland, Norway Radiology 211 1999 211 214
125. S. Bolin, E. Nilsson, and R. Sjodahl Carcinoma of the colon and rectum-growth rate Ann. Surg. 198 1983 151 158
126. J.A. Carlson Tumor doubling time of cutaneous melanoma and its metastasis Am. J. Dermatopathol. 25 2003 291 299
127. M. Yoshino Growth kinetics of hepatocellular carcinoma Jpn. J. Clin. Oncol. 13 1983 45 52
128. T. Nakajima, M. Moriguchi, Y. Mitsumoto, T. Katagishi, H. Kimura, H. Shintani, T. Deguchi, T. Okanoue, K. Kagawa, and T. Ashihara Simple tumor profile chart based on cell kinetic parameters and histologic grade is useful for estimating the natural growth rate of hepatocellular carcinoma Hum. Pathol. 33 2002 92 99
129. Y. Saito, Y. Matsuzaki, M. Doi, T. Sugitani, T. Chiba, M. Abei, J. Shoda, and N. Tanaka Multiple regression analysis for assessing the growth of small hepatocellular carcinoma: the MIB-1 labeling index is the most effective parameter J. Gastroenterol. 33 1998 229 235
130. S. Nakasu, Y. Nakasu, M. Nakajima, M. Yokoyama, M. Matsuda, and J. Handa Potential doubling time and tumour doubling time in meningiomas and neurinomas Acta Neurochir. (Wien) 138 1996 763 770
131. M.R. Paling, and T.H. Shawker Abdominal ultrasound in advanced ovarian carcinoma J. Clin. Ultrasound 9 1981 435 441
132. H. Furukawa, R. Iwata, and N. Moriyama Growth rate of pancreatic adenocarcinoma: initial clinical experience Pancreas 22 2001 366 369
133. Y. Tanaka, K. Hongo, T. Tada, K. Sakai, Y. Kakizawa, and S. Kobayashi Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index J. Neurosurg. 98 2003 359 365
134. H.P. Schmid, J.E. McNeal, and T.A. Stamey Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume Cancer 71 1993 2031 2040
135. S. Ozono, N. Miyao, T. Igarashi, K. Marumo, H. Nakazawa, M. Fukuda, T. Tsushima, N. Tokuda, J. Kawamura, and M. Murai Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer Jpn. J. Clin. Oncol. 34 2004 82 85
136. T. Arai, T. Kuroishi, Y. Saito, Y. Kurita, T. Naruke, and M. Kaneko Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group Jpn. J. Clin. Oncol. 24 1994 199 204
137. Y. Takahashi, M. Mai, and S. Kusama Factors influencing growth rate of recurrent stomach cancers as determined by analysis of serum carcinoembryonic antigen Cancer 75 1995 1497 1502
138. F.G. Blankenberg, R.L. Teplitz, W. Ellis, M.S. Salamat, B.H. Min, L. Hall, D.B. Boothroyd, I.M. Johnstone, and D.R. Enzmann The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas AJNR Am. J. Neuroradiol. 16 1995 1001 1012
139. K. Usuda, Y. Saito, M. Sagawa, M. Sato, K. Kanma, S. Takahashi, C. Endo, Y. Chen, A. Sakurada, and S. Fujimura Tumor doubling time and prognostic assessment of patients with primary lung cancer Cancer 74 1994 2239 2244
140. K. Tanaka, H. Shimada, M. Miura, Y. Fujii, S. Yamaguchi, I. Endo, H. Sekido, S. Togo, and H. Ike Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis World J. Surg. 28 2004 263 270
141. N. Okazaki, M. Yoshino, T. Yoshida, M. Suzuki, N. Moriyama, K. Takayasu, M. Makuuchi, S. Yamazaki, H. Hasegawa, and M. Noguchi Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report Cancer 63 1989 2207 2210
142. W. Weiss Tumor doubling time and survival of men with bronchogenic carcinoma Chest 65 1974 3 8
143. E.P. Malaise, N. Chavaudra, A. Charbit, and M. Tubiana Relationship between the growth rate of human metastases, survival and pathological type Eur. J. Cancer 10 1974 451 459
144. M.C. Garnett, and P. Kallinteri Nanomedicines and nanotoxicology: some physiological principles Occup. Med. (Lond.) 56 2006 307 311
145. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
146. R. Pasqualini, W. Arap, and D.M. McDonald Probing the structural and molecular diversity of tumor vasculature Trends Mol. Med. 8 2002 563 571
147. J.A. Nagy, S.H. Chang, S.C. Shih, A.M. Dvorak, and H.F. Dvorak Heterogeneity of the tumor vasculature Semin. Thromb. Hemost. 36 2010 321 331
148. I.O. Ng, R.T. Poon, J.M. Lee, S.T. Fan, M. Ng, and W.K. Tso Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma Am. J. Clin. Pathol. 116 2001 838 845
149. F. Dunphy, B.C. Stack Jr., J.H. Boyd, T.L. Dunleavy, H.J. Kim, and C.H. Dunphy Microvessel density in advanced head and neck squamous cell carcinoma before and after chemotherapy Anticancer. Res. 22 2002 1755 1758
150. H.C. Hollingsworth, E.C. Kohn, S.M. Steinberg, M.L. Rothenberg, and M.J. Merino Tumor angiogenesis in advanced stage ovarian carcinoma Am. J. Pathol. 147 1995 33 41
151. A. Yuan, P.C. Yang, C.J. Yu, Y.C. Lee, Y.T. Yao, C.L. Chen, L.N. Lee, S.H. Kuo, and K.T. Luh Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer Am. J. Respir. Crit. Care Med. 152 1995 2157 2162
152. S.G. Sharma, N. Aggarwal, S.D. Gupta, M.K. Singh, R. Gupta, and A.K. Dinda Angiogenesis in renal cell carcinoma: correlation of microvessel density and microvessel area with other prognostic factors Int. Urol. Nephrol. 43 2011 125 129
153. S. Bosari, A.K. Lee, R.A. DeLellis, B.D. Wiley, G.J. Heatley, and M.L. Silverman Microvessel quantitation and prognosis in invasive breast carcinoma Hum. Pathol. 23 1992 755 761
154. N. Weidner, J.P. Semple, W.R. Welch, and J. Folkman Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma N. Engl. J. Med. 324 1991 1 8
155. C.H. Graham, J. Rivers, R.S. Kerbel, K.S. Stankiewicz, and W.L. White Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas Am. J. Pathol. 145 1994 510 514
156. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am. J. Pathol. 143 1993 401 409
157. O. Abulafia, W.E. Triest, D.M. Sherer, C.C. Hansen, and F. Ghezzi Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma Obstet. Gynecol. 86 1995 479 485
158. P.B. Vermeulen, D. Verhoeven, G. Hubens, E. Van Marck, G. Goovaerts, M. Huyghe, E.A. De Bruijn, A.T. Van Oosterom, and L.Y. Dirix Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas Ann. Oncol. 6 1995 59 64
159. S. Svagzdys, V. Lesauskaite, D. Pavalkis, I. Nedzelskiene, D. Pranys, and A. Tamelis Microvessel density as new prognostic marker after radiotherapy in rectal cancer BMC Cancer 9 2009 95
160. S. Behrem, K. Zarkovic, N. Eskinja, and N. Jonjic Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma Croat. Med. J. 46 2005 417 422
161. S.C. Piscitelli, K.A. Rodvold, D.A. Rushing, and D.A. Tewksbury Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer Clin. Pharmacol. Ther. 53 1993 555 561
162. M. Longmire, P.L. Choyke, and H. Kobayashi Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats Nanomedicine (Lond.) 3 2008 703 717
163. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A. 95 1998 4607 4612
164. T. Horn, J.H. Henriksen, and P. Christoffersen The sinusoidal lining cells in normal human liver. A scanning electron microscopic investigation Liver 6 1986 98 110
165. H. Uchino, Y. Matsumura, T. Negishi, F. Koizumi, T. Hayashi, T. Honda, N. Nishiyama, K. Kataoka, S. Naito, and T. Kakizoe Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats Br. J. Cancer 93 2005 678 687
166. P.E. Colombo, M. Boustta, S. Poujol, F. Pinguet, P. Rouanet, F. Bressolle, and M. Vert Biodistribution of doxorubicin-alkylated poly(l-lysine citramide imide) conjugates in an experimental model of peritoneal carcinomatosis after intraperitoneal administration Eur. J. Pharm. Sci. 31 2007 43 52
167. C.D. Conover, R.B. Greenwald, A. Pendri, C.W. Gilbert, and K.L. Shum Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker Cancer Chemother. Pharmacol. 42 1998 407 414
168. M. Harada, J. Murata, Y. Sakamura, H. Sakakibara, S. Okuno, and T. Suzuki Carrier and dose effects on the pharmacokinetics of T-0128, a camptothecin analogue-carboxymethyl dextran conjugate, in non-tumor- and tumor-bearing rats J. Control. Release 71 2001 71 86
169. C. Li, R.A. Newman, Q.P. Wu, S. Ke, W. Chen, T. Hutto, Z. Kan, M.D. Brannan, C. Charnsangavej, and S. Wallace Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor Cancer Chemother. Pharmacol. 46 2000 416 422
170. T. Schluep, J. Cheng, K.T. Khin, and M.E. Davis Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice Cancer Chemother. Pharmacol. 57 2006 654 662
171. J.G. Shiah, M. Dvorak, P. Kopeckova, Y. Sun, C.M. Peterson, and J. Kopecek Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice Eur. J. Cancer 37 2001 131 139
172. R. Song, Y. Joo Jun, J. Ik Kim, C. Jin, and Y.S. Sohn Synthesis, characterization, and tumor selectivity of a polyphosphazene-platinum(II) conjugate J. Control. Release 105 2005 142 150
173. A. Sparreboom, C.D. Scripture, V. Trieu, P.J. Williams, T. De, A. Yang, B. Beals, W.D. Figg, M. Hawkins, and N. Desai Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin. Cancer Res. 11 2005 4136 4143
174. S. Sugahara, M. Kajiki, H. Kuriyama, and T.R. Kobayashi Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992) J. Control. Release 117 2007 40 50
175. X. Wang, G. Zhao, S. Van, N. Jiang, L. Yu, D. Vera, and S.B. Howell Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts Cancer Chemother. Pharmacol. 65 2010 515 526
176. Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, and K. Kataoka Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjug. Chem. 16 2005 122 130
177. H. Cabral, N. Nishiyama, and K. Kataoka Optimization of (1,2-diamino-cyclohexane) platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity J. Control. Release 121 2007 146 155
178. A.A. Gabizon Liposome circulation time and tumor targeting: implications for cancer chemotherapy Adv. Drug Deliv. Rev. 16 1995 285 294
179. M.L. Immordino, P. Brusa, S. Arpicco, B. Stella, F. Dosio, and L. Cattel Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J. Control. Release 91 2003 417 429
180. R. Jukanti, G. Devraj, A.S. Shashank, and R. Devraj Biodistribution of ascorbyl palmitate loaded doxorubicin pegylated liposomes in solid tumor bearing mice J. Microencapsul. 28 2011 142 149
181. H.J. Lim, D. Masin, N.L. McIntosh, T.D. Madden, and M.B. Bally Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors J. Pharmacol. Exp. Ther. 292 2000 337 345
182. D.E. Lopes de Menezes, N. Hudon, N. McIntosh, and L.D. Mayer Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin Clin. Cancer Res. 6 2000 2891 2902
183. M.S. Newman, G.T. Colbern, P.K. Working, C. Engbers, and M.A. Amantea Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice Cancer Chemother. Pharmacol. 43 1999 1 7
184. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, K. Nishio, Y. Matsumura, and K. Kataoka Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983
185. S. Unezaki, K. Maruyama, O. Ishida, A. Suginaka, J.-i. Hosoda, and M. Iwatsuru Enhanced tumor targeting and improved antitumor activity of doxorubicin by long-circulating liposomes containing amphipathic poly(ethylene glycol) Int. J. Pharm. 126 1995 41 48
186. J. Vaage, E. Barbera-Guillem, R. Abra, A. Huang, and P. Working Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts Cancer 73 1994 1478 1484
187. X.B. Xiong, Y. Huang, W.L. Lu, X. Zhang, H. Zhang, T. Nagai, and Q. Zhang Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic J. Control. Release 107 2005 262 275
188. M. Yokoyama, T. Okano, Y. Sakurai, S. Fukushima, K. Okamoto, and K. Kataoka Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system J. Drug Target. 7 1999 171 186
189. H.S. Yoo, and T.G. Park Folate receptor targeted biodegradable polymeric doxorubicin micelles J. Control. Release 96 2004 273 283
190. J.Q. Zhang, Z.R. Zhang, H. Yang, Q.Y. Tan, S.R. Qin, and X.L. Qiu Lyophilized paclitaxel magnetoliposomes as a potential drug delivery system for breast carcinoma via parenteral administration: in vitro and in vivo studies Pharm. Res. 22 2005 573 583
191. K.M. Laginha, S. Verwoert, G.J. Charrois, and T.M. Allen Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors Clin. Cancer Res. 11 2005 6944 6949
192. C.L. Peng, P.S. Lai, F.H. Lin, S. Yueh-Hsiu Wu, and M.J. Shieh Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles Biomaterials 30 2009 3614 3625
193. M. Rafi, H. Cabral, M.R. Kano, P. Mi, C. Iwata, M. Yashiro, K. Hirakawa, K. Miyazono, N. Nishiyama, and K. Kataoka Polymeric micelles incorporating (1,2-diaminocyclohexane) platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis J. Control. Release 159 2012 189 196
194. Y. Saito, M. Yasunaga, J. Kuroda, Y. Koga, and Y. Matsumura Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour Eur. J. Cancer 46 2010 650 658
195. A. Takahashi, N. Ohkohchi, M. Yasunaga, J. Kuroda, Y. Koga, H. Kenmotsu, T. Kinoshita, and Y. Matsumura Detailed distribution of NK012, an SN-38-incorporating micelle, in the liver and its potent antitumor effects in mice bearing liver metastases Clin. Cancer Res. 16 2010 4822 4831